Recent experience includes:
Oxford Medical Simulation
Advised Oxford Medical Simulation in connection with its £10million Series A raise, which was led by Frog Capital with follow-on capital from ACF Investors, existing shareholders and strategic partners. The company works with institutions to support the healthcare workforce by providing virtual reality training for patient care.
UCB Ventures, BGF and 4BIO Capital
Advised UCB Ventures, BGF and 4BIO Capital, who led the over-subscribed Series A funding round of $25million in Vianautis Bio.
LifeArc
Advised LifeArc in relation to multiple primary investments as part of their venture investment programme. LifeArc is a British life science medical research charity with a commitment to investing up to £1.3 billion by 2030 on investments focused on breakthrough patient-focused research that seeks to transform how diseases are identified and treated.
Flarin
Advised Flarin, the joint pain relief brand, on its fundraise through existing investor IW Capital and through ITV's Media for Equity investment fund. ITV has agreed to invest up to £5 million of advertising inventory across its channels in return for a minority equity stake in Flarin. IW Capital has subscribed for new shares following previous equity investments in the Company.
Apposite Capital
Advised Apposite Capital, a healthcare investor, on its investment in medical device company, Emblation. Established in 2007, Emblation designs, manufactures and commercialises next generation microwave-based solutions for a range of skin conditions. Its products, which are currently sold in the UK, North America and Australia, have been used in more than 130,000 treatments. This investment will support Emblation's international growth, as well as enable it to expand its technology platform.
Private equity investor and an inventor
Advised a private equity investor and an inventor in relation to a diagnostic and treatment device in the ENT area. We provided strategic and practical legal advice to clarify the position on ownership and control over the product, and to prepare the ground for financial investment into and commercialisation of the device.
capiton AG
Advised private equity firm capiton on a general partner-led single asset secondary transaction relating to the KD Pharma Group.
Woodford Patient Capital Trust plc
Advised on the set up and launch of Woodford Patient Capital Trust plc, an innovative investment trust offering exposure to early-stage companies with outstanding intellectual property and long-term return opportunities.
e-therapeutics plc
Acted for e-therapeutics plc on a number of transactions including:
- a £13.5 million equity fundraise, the proceeds of which will facilitate a number of initiatives to accelerate growth, with a focus on expanding the company’s in-house pipeline of first-in-class RNAi candidates derived from its computational platform, and further developing cell type-specific computational tools and datasets.
- a £22.5 million all equity fundraise, which comprises a placing with institutional investors, as well as direct subscriptions from individual investors and an offer to retail and other investors via the PrimaryBid platform.
- a £12.4 million equity fundraise.
French fund manager
Advised on structuring and establishing a life sciences venture fund.
Optum
Advised Optum, as the lead investor, investing by way of subscription for Series A Shares, in Oxford VR Limited, resulting in Optum holding 20% of the fully diluted share capital in Oxford VR. Oxford VR is technology company which has developed immersive virtual reality software aimed at treating mental health issues such as anxiety.
Acacia Pharma Group plc
Advised Euronext Brussels-listed Acacia Pharma Group plc on its successful €25 million fundraising through the placing of 12.5 million new ordinary shares at €2 per share with institutional investors in Europe and the US.
UCB
Advised UCB on various strategic investments alongside financial investors in various early stage portfolio companies, in both the US and throughout Europe. These included an early stage spin-out from a UK university involved in pioneering cell therapy technology, a Switzerland-based company developing a RNA-targeting drug development platform, a Spanish company developing a neurological chronic pain medical device and a US company developing a novel gene therapy platform for second generation delivery vectors.
State Bank of India (SBI)
Advised the SBI on a US$1 billion credit facility to the Government of Sri Lanka for the purposes of importing medicine, food and other essential items.
Hayfin
Advised Hayfin as co-lead investor in a €320 million Single-Asset Continuation Fund established by Impilo to support the next phase of ownership of Immedica Pharma AB, a pharmaceutical company focused on speciality medicines for rare diseases.
